Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBP Corbus Pharmaceuticals	$8.96 +3.3%	$8.52	$4.64 ▼ $61.89	$106.25M	3.2	115,821 shs	80,521 shs
CRDL Cardiol Therapeutics	$1.13 +9.7%	$1.35	$0.77 ▼ $2.63	$85.15M	1.05	878,721 shs	990,718 shs
LSTA Lisata Therapeutics	$2.62 -5.4%	$2.63	$1.87 ▼ $4.20	$24.25M	0.93	63,044 shs	6,902 shs
TVRD Tvardi Therapeutics	$23.60 -2.2%	$25.07	$8.13 ▼ $34.31	$225.88M	0.21	32,464 shs	22,159 shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBP Corbus Pharmaceuticals	+2.85%	-7.17%	+4.84%	+19.42%	-84.67%
CRDL Cardiol Therapeutics	+4.47%	-19.53%	-20.16%	-10.04%	-48.76%
LSTA Lisata Therapeutics	+6.54%	+7.78%	+2.21%	+21.49%	-5.13%
TVRD Tvardi Therapeutics	+0.88%	-8.39%	-11.74%	+2,412,999,900.00%	+2,412,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBP Corbus Pharmaceuticals	4.4142 of 5 stars	3.6	3.0	0.0	4.7	2.9	2.5	0.6
CRDL Cardiol Therapeutics	2.8369 of 5 stars	3.7	4.0	0.0	0.0	3.0	0.0	0.6
LSTA Lisata Therapeutics	2.8977 of 5 stars	3.5	4.0	0.0	0.0	2.5	0.0	1.3
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBP Corbus Pharmaceuticals	3.10	Buy	$49.00	446.88% Upside
CRDL Cardiol Therapeutics	3.33	Buy	$8.00	607.96% Upside
LSTA Lisata Therapeutics	3.00	Buy	$23.50	796.95% Upside
TVRD Tvardi Therapeutics	3.00	Buy	$64.25	172.25% Upside

Current Analyst Ratings Breakdown

Latest LSTA, CRDL, TVRD, and CRBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/6/2025	CRBP Corbus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$56.00 ➝ $53.00
7/30/2025	CRBP Corbus Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$28.00
7/15/2025	LSTA Lisata Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $32.00
7/14/2025	TVRD Tvardi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$62.00
7/12/2025	CRBP Corbus Pharmaceuticals	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/11/2025	TVRD Tvardi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$52.00
6/12/2025	TVRD Tvardi Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$78.00
6/2/2025	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/21/2025	TVRD Tvardi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00

(Data available from 8/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	$9.06 per share	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.22 per share	N/A
LSTA Lisata Therapeutics	$1M	22.95	N/A	N/A	$2.37 per share	1.11
TVRD Tvardi Therapeutics	$7.14M	30.94	N/A	N/A	($3.02) per share	-7.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBP Corbus Pharmaceuticals	-$40.21M	-$4.76	N/A	N/A	N/A	N/A	-43.65%	-39.62%	N/A
CRDL Cardiol Therapeutics	-$26.77M	-$0.34	N/A	N/A	N/A	N/A	-209.63%	-141.09%	N/A
LSTA Lisata Therapeutics	-$19.99M	-$2.23	N/A	N/A	N/A	N/A	-69.68%	-59.44%	N/A
TVRD Tvardi Therapeutics	-$70.87M	N/A	0.00	∞	N/A	-595.39%	-710.04%	-79.00%	N/A

Latest LSTA, CRDL, TVRD, and CRBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	LSTA Lisata Therapeutics	-$0.65	-$0.54	+$0.11	-$0.54	N/A	$0.07 million
8/5/2025	Q2 2025	CRBP Corbus Pharmaceuticals	-$1.55	-$1.44	+$0.11	-$1.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBP Corbus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A
TVRD Tvardi Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBP Corbus Pharmaceuticals	N/A	9.21	9.21
CRDL Cardiol Therapeutics	0.01	3.26	3.26
LSTA Lisata Therapeutics	N/A	5.77	5.77
TVRD Tvardi Therapeutics	N/A	32.48	31.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBP Corbus Pharmaceuticals	64.64%
CRDL Cardiol Therapeutics	12.49%
LSTA Lisata Therapeutics	8.94%
TVRD Tvardi Therapeutics	44.66%

Insider Ownership

Company	Insider Ownership
CRBP Corbus Pharmaceuticals	4.00%
CRDL Cardiol Therapeutics	5.25%
LSTA Lisata Therapeutics	9.10%
TVRD Tvardi Therapeutics	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBP Corbus Pharmaceuticals	40	12.26 million	11.77 million	Optionable
CRDL Cardiol Therapeutics	20	82.68 million	78.34 million	Not Optionable
LSTA Lisata Therapeutics	30	8.76 million	7.96 million	Not Optionable
TVRD Tvardi Therapeutics	80	9.36 million	9.07 million	N/A

LSTA, CRDL, TVRD, and CRBP Headlines

Recent News About These Companies

Raymond James Initiates Coverage of Tvardi Therapeutics (TVRD) with Outperform Recommendation

July 15, 2025 | msn.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | finance.yahoo.com

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference

July 15, 2025 | businesswire.com

Tvardi Therapeutics (NASDAQ:TVRD) Earns Outperform Rating from Analysts at Raymond James Financial

July 14, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TVRD FY2025 Earnings

July 14, 2025 | marketbeat.com

Cantor Fitzgerald Initiates Coverage of Tvardi Therapeutics (TVRD) with Overweight Recommendation

July 12, 2025 | msn.com

Tvardi Therapeutics Inc News (TVRD) - Investing.com

June 27, 2025 | investing.com

TVRD Tvardi Therapeutics, Inc.

June 19, 2025 | seekingalpha.com

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating

June 13, 2025 | uk.investing.com

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

June 12, 2025 | benzinga.com

Tvardi Therapeutics Inc (TVRD)

June 7, 2025 | investing.com

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA, CRDL, TVRD, and CRBP Company Descriptions

Corbus Pharmaceuticals NASDAQ:CRBP

$8.96 +0.29 (+3.34%)

Closing price 04:00 PM Eastern

Extended Trading

$8.85 -0.11 (-1.23%)

As of 07:32 PM Eastern

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

Cardiol Therapeutics NASDAQ:CRDL

$1.13 +0.10 (+9.71%)

Closing price 04:00 PM Eastern

Extended Trading

$1.12 -0.01 (-0.88%)

As of 07:55 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Lisata Therapeutics NASDAQ:LSTA

$2.62 -0.15 (-5.42%)

Closing price 03:51 PM Eastern

Extended Trading

$2.66 +0.04 (+1.53%)

As of 04:04 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

Tvardi Therapeutics NASDAQ:TVRD

$23.60 -0.53 (-2.20%)

As of 04:00 PM Eastern

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time